Sponsor: Zai Biopharmaceutical
Sponsor Study ID: ZL-1310-001
Study Title: An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
CTO #: 103950
NCT Number: NCT06179069
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To characterize the safety and tolerability of different dose levels of ZL-1310, including dose‑limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose (RD).